索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]王鸣旺,陆伦根.以PPAR为靶点的代谢功能障碍相关脂肪性肝病治疗药物研究进展[J].国际消化病杂志,2024,06:361-364，375.
点击复制

以PPAR为靶点的代谢功能障碍相关脂肪性肝病治疗药物研究进展(PDF)

《国际消化病杂志》[ISSN:1673-534X/CN:31-1953/R]

期数:
2024年06期
页码:
361-364，375
栏目:
综述
出版日期:
2024-12-20

文章信息/Info

Title:
-
作者:
王鸣旺; 陆伦根
201620 上海交通大学医学院附属第一人民医院消化科
Author(s):
-
关键词:
MASLD ; PPAR ; 药物研发; 临床试验
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-534X.2024.06.003
文献标识码:
-
摘要:
代谢功能障碍相关脂肪性肝病（MASLD）是一类与代谢功能障碍相关的肝脂肪变性疾病，可进展为肝硬化及肝细胞癌。MASLD的患病率较高且呈升高趋势，是亟待解决的全球公共卫生问题。过氧化物酶体增殖物激活受体（PPAR）在代谢性疾病中发挥着重要作用，是治疗MASLD的重要靶点。目前，靶向PPAR药物的研发已取得了一定进展。该文就以PPAR为靶点的MASLD治疗药物的研究进展作一综述，以期为MASLD的治疗提供参考。
Abstract:
-

参考文献/References

1Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature[J]. Ann Hepatol, 2024, 29(1): 101133.
2 王晓菲, 黄淑田. 非酒精性脂肪性肝病与心血管疾病[J]. 国际心血管病杂志, 2024, 51(3): 167-170.
3Le MH, Le DM, Baez TC, et al. Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 persons[J]. J Hepatol, 2023, 79(2): 287-295.
4Zhou F, Zhou J, Wang W, et al. Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: a systematic review and meta-analysis[J]. Hepatology, 2019, 70(4): 1119-1133.
5Lu R, Liu Y, Hong T. Epidemiological characteristics and management of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis in China: A narrative review[J]. Diabetes Obes Metab, 2023, 25 Suppl 1: 13-26.
6FDA. FDA approves first treatment for patients with liver scarring due to fatty liver disease[EB/OL]. (2024-03-14) [2024-03-27] https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease.
7Harrison SA, Bedossa P, Guy CD, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis[J]. N Engl J Med, 2024, 390(6): 497-509.
8Khaznadar F, Khaznadar O, Petrovic A, et al. MAFLD pandemic:updates in pharmacotherapeutic approach development[J]. Curr Issues Mol Biol, 2024, 46(7): 6300-6314.
9Gross B, Pawlak M, Lefebvre P, et al. PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD[J]. Nat Rev Endocrinol, 2017, 13(1): 36-49.
10 Berthier A, Johanns M, Zummo FP, et al. PPARs in liver physiology[J]. Biochim Biophys Acta Mol Basis Dis, 2021, 1867(5): 166097.
11 Cusi K, Orsak B, Bril F, et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial[J]. Ann Intern Med, 2016, 165(5): 305-315.
12 Violi F, Cangemi R. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis[J]. N Engl J Med, 2010, 363(12): 1185-1186; author reply 1186.
13 Wang Z, Du H, Zhao Y, et al. Response to pioglitazone in non-alcoholic fatty liver disease patients with vs. without type 2 diabetes:A meta-analysis of randomized controlled trials[J]. Front Endocrinol (Lausanne), 2023, 14: 1111430.
14 Majzoub AM, Nayfeh T, Barnard A, et al. Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH[J]. Aliment Pharmacol Ther, 2021, 54(7): 880-889.
15 Yan H, Wu W, Chang X, et al. Gender differences in the efficacy of pioglitazone treatment in nonalcoholic fatty liver disease patients with abnormal glucose metabolism[J]. Biol Sex Differ, 2021, 12(1): 1.
16 Yoneda M, Kobayashi T, Honda Y, et al. Combination of tofogliflozin and pioglitazone for NAFLD: Extension to the ToPiND randomized controlled trial[J]. Hepatol Commun, 2022, 6(9): 2273-2285.
17 Jianfang F, Wanxia X, Xiling G, et al. Effect and safety of pioglitazone-metformin tablets in the treatment of newly diagnosed type 2 diabetes patients with nonalcoholic fatty liver disease in Shaanxi Province: A randomized, double-blinded, double-simulated multicenter study[J]. J Diabetes Res, 2023, 2023: 2044090.
18 Jacques V, Bolze S, Hallakou-Bozec S, et al. Deuterium-stabilized (R)-pioglitazone (PXL065) is responsible for pioglitazone efficacy in NASH yet exhibits little to no PPARγ activity[J]. Hepatol Commun, 2021, 5(8): 1412-1425.
19 Harrison SA, Thang C, Bolze S, et al. Evaluation of PXL065 -deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase Ⅱ randomized placebo-controlled trial (DESTINY-1)[J]. J Hepatol, 2023, 78(5): 914-925.
20 Gawrieh S, Noureddin M, Loo N, et al. Saroglitazar, a PPAR-α/γ agonist, for treatment of NAFLD: a randomized controlled double-blind phase 2 trial[J]. Hepatology, 2021, 74(4): 1809-1824.
21 Gupta T, Kaushik P, Mittal R. Saroglitazaar is effective in improving liver stiffness measurement and liver enzymes in nonalcoholic steatohepatitis[J]. Hepatology, 2023, 78: S160-S161.
22 Siddiqui MS, Idowu MO, Parmar D, et al. A phase 2 double blinded, randomized controlled trial of saroglitazar in patients with nonalcoholic steatohepatitis[J]. Clin Gastroenterol Hepatol, 2021, 19(12): 2670-2672.
23 Boubia B, Poupardin O, Barth M, et al. Design, synthesis, and evaluation of a novel series of indole sulfonamide peroxisome proliferator activated receptor (PPAR) α/γ/δ triple activators:Discovery of lanifibranor, a new antifibrotic clinical candidate[J]. J Med Chem, 2018, 61(6): 2246-2265.
24 Lefere S, Puengel T, Hundertmark J, et al. Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages☆[J]. J Hepatol, 2020, 73(4): 757-770.
25 Wettstein G, Luccarini JM, Poekes L, et al. The new-generation pan-peroxisome proliferator-activated receptor agonist IVA337 protects the liver from metabolic disorders and fibrosis[J]. Hepatol Commun, 2017, 1(6): 524-537.
26 Francque SM, Bedossa P, Ratziu V, et al. A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH[J]. N Engl J Med, 2021, 385(17): 1547-1558.
27 Sven MF, Pierre B, Manal FA, et al. A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non-alcoholic steatohepatitis: Design of the NATIVE study[J]. Contemp Clin Trials, 2020, 98: 106170.
28 Nakajima A, Eguchi Y, Yoneda M, et al. Randomised clinical trial:Pemafibrate, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), versus placebo in patients with non-alcoholic fatty liver disease[J]. Aliment Pharmacol Ther, 2021, 54(10): 1263-1277.
29 Das Pradhan A, Glynn RJ, Fruchart JC, et al. Triglyceride lowering with pemafibrate to reduce cardiovascular risk[J]. N Engl J Med, 2022, 387(21): 1923-1934.
30 Sasaki Y, Asahiyama M, Tanaka T, et al. Pemafibrate, a selective PPARα modulator, prevents non-alcoholic steatohepatitis development without reducing the hepatic triglyceride content[J]. Sci Rep, 2020, 10(1): 7818.
31 Ratziu V, Harrison SA, Francque S, et al. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-α and -δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening[J]. Gastroenterology, 2016, 150(5): 1147-1159. e5.
32 ClinicalTrials.gov. Phase 3 study to evaluate the efficacy and safety of elafibranor versus placebo in patients with nonalcoholic steatohepatitis (NASH) (RESOLVE-IT)[EB/OL]. (2022-03-23) [2024-03-27] https://classic.clinicaltrials.gov/ct2/show/results/NCT0 2704403?term=Elafibranor&cond=NAFLD&draw=2&rank=4.
33 Watkins PB, Kleiner DE, Bedossa P. An independent blinded review of suspected drug-induced liver injury (DILI) in nonalcoholic steatohepatitis (NASH) patients by a panel of pathologists and hepatologists: lessons learned from the seladelpar hepatotoxicity review committee (SHRC)[EB/OL]. (2021-06-18) [2024-03-27] https://www.postersessiononline.eu/173580348_eu/congresos/ILC2021/aula/-PO_1504_ILC2021.pdf
34 Harrison SA, Gunn NT, Khazanchi A, et al. A 52-week multi-center double-blind randomized phase 2 study of seladelpar, a potent and selective peroxisome proliferator-activated receptor delta (PPAR-delta) agonist, in patients with nonalcoholic steatohepatitis (NASH)[J]. Hepatology, 2020, 72(S1): 1042A-1043A.
35 范建高, 李小英. NAFLD更名MAFLD、MASLD ：背景、异同、对策[J]. 中华肝脏病杂志, 2023, 31(8): 789-792.
36 Rich NE, Oji S, Mufti AR, et al. Racial and ethnic disparities in nonalcoholic fatty liver disease prevalence, severity, and outcomes in the United States: a systematic review and meta-analysis[J]. Clin Gastroenterol Hepatol, 2018, 16(2): 198-210. e2.
37 Kim D, Kim WR. Nonobese fatty liver disease[J]. Clin Gastroenterol Hepatol, 2017, 15(4): 474-485.
38 国家药品监督管理局. 非酒精性脂肪性肝炎治疗药物临床试验指导原则（试行）[EB/OL]. (2019-12-17) [2024-03-27] https://www. nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/20191220141201879.html
39 FDA. Regulatory perspectives for development of drugs for treatment of NASH[EB/OL]. (2021-01-29) [2024-03-27] https://www.fda. gov/drugs/news-events-human-drugs/regulatory-perspectives-development-drugs-treatment-nash-01292021.
40 Harrison SA, Allen AM, Dubourg J, et al. Challenges and opportunities in NASH drug development[J]. Nat Med, 2023, 29(3):562-573.

备注/Memo

备注/Memo:
-
更新日期/Last Update: 2024-12-20